News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
REMEGEN Grants Vor Bio Exclusive Development Rights for Telitacicept Outside Greater China
REMEGEN (09995.HK) announced that it will grant Vor Bio (VOR.US) a paid license for its self-developed Telitacicept with intellectual property rights, and Vor Bio will obtain the e...
Reset
Send
The window will close in 5 seconds
REMEGEN Grants Vor Bio Exclusive Development Rights for Telitacicept Outside Greater China
Close
Recommend
4
Positive
7
Negative
3
 
SHORT SELL
 
STOCK INFO

REMEGEN (09995.HK)  -3.650 (-6.166%)    Short selling $98.12M; Ratio 8.795%   announced that it will grant Vor Bio (VOR.US)      a paid license for its self-developed Telitacicept with intellectual property rights, and Vor Bio will obtain the exclusive rights to develop and commercialize Telitacicept worldwide (excluding Greater China (i.e. Mainland China, Hong Kong, Macau and Taiwan)).

In addition, Vor Bio will issue warrants to Yantai Rongpu, which is wholly-owned by REMEGEN, as partial consideration for the rights granted to Vor Bio by REMEGEN under the license agreement.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-27 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.